Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is cu...
Q1 2026
May 12, 2026
FY 2025
Dec 31, 2025
Q4 2025
Q3 2025
Sep 29, 2025
Q1 2025
Mar 31, 2025